| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:00 | Futura Medical PLC - Notice of Results & Investor Presentation | 1 | RNS | ||
| 23.03. | Futura Medical "very pleased" by Eroxon testing results | 16 | Alliance News | ||
| 23.03. | AIM Market Roundup: Quadrise, Iomart, Futura Medical | 3 | The Armchair Trader | ||
| 23.03. | Futura Medical reports positive trial results for Eroxon products | 1 | Investing.com | ||
| 23.03. | Futura Medical meldet positive Studienergebnisse für Eroxon-Produkte | 1 | Investing.com Deutsch | ||
| 23.03. | Futura Medical PLC - Positive Eroxon & Eroxon "Intense" HUT results | - | RNS | ||
| 18.03. | Futura Medical PLC - Formal Grant of US Patent | 1 | RNS | ||
| 05.02. | Futura Medical PLC - Patent notice of allowance granted for the US | 5 | RNS | ||
| FUTURA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 04.02. | TRADING UPDATES: Futura Medical says 2025 revenue beats own guidance | 2 | Alliance News | ||
| 04.02. | Futura Medical PLC - Trading Update | 2 | RNS | ||
| 12.01. | Futura Medical PLC - Results of WSD4000 Early Feasibility Study | 13 | RNS | ||
| 07.01. | Spreadex reduces stake in Futura Medical to 3.92% | 6 | Investing.com | ||
| 07.01. | Spreadex reduziert Anteil an Futura Medical auf 3,92 % | - | Investing.com Deutsch | ||
| 07.01. | Futura Medical PLC - Notification of major holdings | - | RNS | ||
| 31.12.25 | Futura Medical PLC - Total Voting Rights | 1 | RNS | ||
| 30.12.25 | Cantor Fitzgerald Europe reduziert Beteiligung an Futura Medical | 6 | Investing.com Deutsch | ||
| 30.12.25 | Cantor Fitzgerald Europe reduces stake in Futura Medical | 1 | Investing.com | ||
| 30.12.25 | Futura Medical PLC - Notification of major holdings | 1 | RNS | ||
| 23.12.25 | Lombard Odier reduces stake in Futura Medical to 12.76% | 1 | Investing.com | ||
| 23.12.25 | Futura Medical PLC - Notification of major holdings | 5 | RNS |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 34,410 | -0,17 % | Novo Nordisk setzt verstärkt auf Künstliche Intelligenz | Novo Nordisk geht eine strategische Partnerschaft mit OpenAI ein. Man will damit komplexe Datensätze analysieren, interessante Wirkstoffkandidaten identifizieren und die Forschungszeit insgesamt reduzieren.... ► Artikel lesen | |
| GILEAD SCIENCES | 116,82 | -0,10 % | Gilead Sciences, Inc. Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx... ► Artikel lesen | |
| AURORA CANNABIS | 3,126 | +0,39 % | Nach den Tilray-Zahlen: Aurora, Canopy & Co. vor richtungsweisender Berichtssaison | In einer Phase, in der sich das Handelsgeschehen auf die Auswirkungen des Iran-Krieges zu konzentrieren scheint, nimmt die Quartalsberichtssaison Fahrt auf. Für die Cannabis-Unternehmen wird es möglicherweise... ► Artikel lesen | |
| CANOPY GROWTH | 0,989 | +1,50 % | Canopy Growth (CGC) Fueling Optimism With a New Product Line | ||
| TILRAY BRANDS | 5,860 | +0,17 % | International Operations Offer Continued Strength to Tilray Brands (TLRY) | ||
| VERTEX PHARMACEUTICALS | 376,60 | +0,45 % | Is Vertex Pharmaceuticals' Empire in Trouble? | ||
| INNOCAN PHARMA | 4,000 | +1,01 % | InnoCan Pharma ÜBERRASCHT Anleger: Könnte die Aktie jetzt komplett durchstarten? - Das sollten Sie jetzt wissen | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| BIOTEST | 29,200 | -9,32 % | Osborne Clarke berät Grifols S.A. bei der Umwandlung der Biotest AG in eine GmbH & Co. KGaA | ||
| CRONOS GROUP | 2,250 | -1,83 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| SYNBIOTIC | 1,770 | -1,78 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC startet mit operativem Fortschritt, neuen regulatorischen Impulsen und starker Branchenpräsenz ins Frühjahr 2026 | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Marktbericht/Prognose
SYNBIOTIC startet mit operativem Fortschritt, neuen regulatorischen Impulsen und starker Branchenpräsenz ins Frühjahr... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Resignation of Director | Vancouver, British Columbia--(Newsfile Corp. - April 8, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the cannabis... ► Artikel lesen | |
| EYEPOINT | 12,500 | -1,57 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| EDWARDS LIFESCIENCES | 68,78 | -0,06 % | TD Cowen reiterates Edwards Lifesciences stock rating on TAVR strength | ||
| ORGANIGRAM GLOBAL | 1,176 | -5,92 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen |